April 19, 2022 at 8:00 AM EDT
EYENOVIA ANNOUNCES POSTER PRESENTATION AT THE 2022 AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose array print (MAP™) spray using the company’s proprietary Optejet® dispenser
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will present an ePoster at the American Society of Cataract and Refractive Surgery Annual Meeting, which is being held April 23-26 in Washington, D.C.
Details of the ePoster presentation are as follows:
Poster Title: Evaluation of Two Mydriatic Dosing Regimens Delivered by MICRO-Array Print Technology for Comparison of Pupil Dilation SPEED
ASCRS Poster ID: 84369
Presenting author: Arturo Chayet, M.D.
Location: This is an ePoster that will be available at kiosks throughout the conference.
Summary: This study demonstrated the speed to clinically meaningful dilation from a single spray of Microdose Array Print (MAP) Dispenser (Optejet) administered tropicamide-phenylephrine fixed combination solution.
The study results showed that almost three out of four patients reached clinically meaningful dilation by 15 minutes (6mm or greater dilation). The MAP technology facilitated accurate and efficient topical ocular administration with 98% of doses successfully administered on first attempt. There were no ocular or systemic adverse events reported.
Dr. Sean Ianchulev, Chairman, Chief Executive Officer and Chief Medical Officer of Eyenovia, commented, “The results of the SPEED study demonstrated that pupil dilation with our proprietary Optejet dispensing technology is both quick and effective, with drug levels substantially less than could be achieved using traditional eye droppers. This confers many benefits to both ophthalmologists and their patients, the latter being exposed to far less drug and preservatives with Optejet, which can lead to side effects and long-term ocular stress.
The American Society of Cataract and Refractive Surgery (ASCRS) empowers anterior segment surgeons to improve the vision, outcomes, and quality of life of their patients through innovative approaches to Education, Advocacy, and Philanthropy. Since its founding in 1974, ASCRS has been at the forefront of anterior segment surgery and has established itself as a trusted resource for cataract, refractive, cornea, and glaucoma surgeons. For more than 40 years, ASCRS has been committed to advancing the art and science of ophthalmic surgery as a primary source for the latest clinical information, published research, and regulatory updates affecting anterior segment surgeons and the patients they serve. ASCRS innovation is focused on three critical areas: Education, Philanthropy, and Advocacy. We provide our members with robust clinical and practice management education and work with patients, government, and the medical community to promote the delivery and advancement of high-quality eyecare.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Chief Financial Officer
Eyenovia Investor Contact:
LifeSci Advisors, LLC
Eyenovia Media Contact:
Vice President, Commercial Operations